Arrakis Therapeutics

Arrakis Therapeutics

  • Founded: 2017
  • Location: Waltham, MA
  • Employee range: 50 - 200
  • Clinical stage: RD
  • Therapy area: Oncology
  • Drug types: INF, ONC
  • Lead product: Undisclosed
  • Product link:
  • Funding: $75M B Apr 2019; $38M A Feb 2017
  • Investors: venBio, Nextech Invest

job board

Short description:

RNA-targeted small molecules

Drug notes:

Undisclosed RD COVID-19; 4 additional undisclosed programs RD undisclosed

Long description:

Arrakis Therapeutics is developing drugs for neurological disorders and other diseases. Most small molecule drugs act by binding to target proteins. Arrakis is instead building upon the existing drug discovery toolkit to discover small molecule compounds that act directly on RNA. Identification of these RNA-targeted small molecules (rSMs) is achieved through Arrakis’ platform that incorporates in silico and wet lab tools to screen hundreds of targets and analyze the structure activity relationship. Arrakis’ current pipeline includes rSMs that show promise for many diseases including cancer, cardiovascular conditions and neurodegeneration.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy